New insights on genetic damage of some chemotherapies could guide future treatments with less harmful side effects
Peer-Reviewed Publication
Updates every hour. Last Updated: 1-Jul-2025 09:10 ET (1-Jul-2025 13:10 GMT/UTC)
For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues.
Researchers from the Wellcome Sanger Institute, the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust (CUH) and their collaborators analysed blood cell genomes from 23 patients of all ages who had been treated with a range of chemotherapies.
Published today (1 July) in Nature Genetics, the researchers show that many but not all chemotherapy agents cause mutations and premature ageing in healthy blood.
A research team led by Haruyo Yamamoto, Chisa Nakashima, and Atsushi Otsuka from Department of Dermatology, Kindai University Faculty of Medicine, in collaboration with the Faculty of Engineering at Kindai University and other institutions, has developed a diagnostic system that uses artificial intelligence (AI) to accurately identify the type of facial pigmented lesions and support laser treatment decisions. A paper on this study was published online in Cureus, an international medical journal on June 5, 2025.
Scientists at the National Institutes of Health (NIH) have found that two common types of hormone therapy may alter breast cancer risk in women before age 55. Researchers discovered that women treated with unopposed estrogen hormone therapy (E-HT) were less likely to develop the disease than those who did not use hormone therapy. They also found that women treated with estrogen plus progestin hormone therapy (EP-HT) were more likely to develop breast cancer than women who did not use hormone therapy. Together, these results could help to guide clinical recommendations for hormone therapy use among younger women.
Michael Karin, PhD, has long been fascinated by what happens when inflammation—ideally a short-term burst of biological activity to promote healing or fight infection—turns chronic and potentially deadly.
He joined Sanford Burnham Prebys on June 30, 2025, where he will continue investigating how chronic inflammation can promote tumor formation. Karin also will serve as director of the new Center for Metabolic and Liver Diseases.CSHL Professor David Spector and graduate student Wenbo Xu have discovered that the long non-coding RNA LINC01235 helps promote the formation of triple-negative breast cancer. Their findings offer potential inroads to new and much-needed therapies for this deadly disease.